Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

CASI Pharmaceuticals Inc

Current price
5.92 USD +0.32 USD (+5.71%)
Last closed 5.59 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 74 467 184 USD
Yield for 12 month +205.15 %
21.11.2021 - 28.11.2021

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; and CID-103, a human IgG1 anti-CD38 monoclonal antibody. The company has licensing agreements with Juventas Biotechnology (Tianjin) Co., Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Address: 9620 Medical Center Drive, Rockville, MD, United States, 20850


WallStreet Target Price

12 USD

P/E ratio

Dividend Yield

Current Year

+43 107 000 USD

Last Year

+30 168 000 USD

Current Quarter

Last Quarter

+15 259 000 USD

Current Year

+27 280 000 USD

Last Year

+17 611 000 USD

Current Quarter

Last Quarter

+10 987 000 USD

Key Figures CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -24 215 500 USD
Operating Margin TTM -59.38 %
PE Ratio
Return On Assets TTM -16.65 %
PEG Ratio
Return On Equity TTM -59.42 %
Wall Street Target Price 12 USD
Revenue TTM 42 264 000 USD
Book Value 2.15 USD
Revenue Per Share TTM 3.15 USD
Dividend Share
Quarterly Revenue Growth YOY -13.5 %
Dividend Yield
Gross Profit TTM 17 611 000 USD
Earnings Share -3.01 USD
Diluted Eps TTM -3.01 USD
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin -95.64 %

Dividend Analytics CASI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:10
Payout Ratio
Last Split Date 02.06.2022
Dividend Date

Stock Valuation CASI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.5678
Price Sales TTM 1.762
Enterprise Value EBITDA -1.0168
Price Book MRQ 1.6706

Financials CASI

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CASI

For 52 weeks

1.45 USD 5.94 USD
50 Day MA 3.75 USD
Shares Short Prior Month 225 692
200 Day MA 2.74 USD
Short Ratio 3.23
Shares Short 151 147
Short Percent 1.35 %